This HTML5 document contains 40 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n6http://linked.opendata.cz/resource/drugbank/drug/DB05719/identifier/chemspider/
n10http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n7http://linked.opendata.cz/resource/drugbank/drug/DB05719/identifier/drugbank/

Statements

Subject Item
n2:DB05719
rdf:type
n3:Drug
n3:description
Elesclomol is a novel, injectable, drug candidate that kills cancer cells by elevating oxidative stress levels beyond a breaking point, triggering programmed cell death. In preclinical models elesclomol showed potent killing of a broad range of cancer cell types at high doses, and an ability to strongly enhance the efficacy of certain chemotherapy agents, with minimal additional toxicity, at moderate doses. It is being developed by Synta Pharmaceuticals.
n3:generalReferences
# Gehrmann M: Drug evaluation: STA-4783--enhancing taxane efficacy by induction of Hsp70. Curr Opin Investig Drugs. 2006 Jun;7(6):574-80. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16784029 # Berkenblit A, Eder JP Jr, Ryan DP, Seiden MV, Tatsuta N, Sherman ML, Dahl TA, Dezube BJ, Supko JG: Phase I clinical trial of STA-4783 in combination with paclitaxel in patients with refractory solid tumors. Clin Cancer Res. 2007 Jan 15;13(2 Pt 1):584-90. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17255281
n3:group
investigational
n3:indication
Investigated for use/treatment in melanoma.
owl:sameAs
n10:DB05719
dcterms:title
Elesclomol
adms:identifier
n6:265501 n7:DB05719
n3:mechanismOfAction
Elesclomol acts through a novel mechanism of action. Elesclomol has been shown to rapidly cause a dramatic increase in oxidative stress (ROS) inside cancer cells. The prolonged elevation of ROS inside cancer cells induced by elesclomol causes the cell to exceed a critical breaking point and undergo apoptosis. The triggering of the mitochondrial apoptosis pathway is observed within the first six hours of applying elesclomol. Cancer cells operate at a much higher intrinsic level of ROS than normal cells, and have a greatly reduced anti-oxidant capacity compared to normal cells. This leaves them more vulnerable to an agent such as elesclomol that elevates oxidative stress. In similar experiments at similar doses, elesclomol has been found to have little to no impact on normal cells.
n3:synonym
STA-4783
n3:IUPAC-Name
n4:271B462B-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B4631-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B4630-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B462D-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B462E-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B462F-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B4629-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B4627-363D-11E5-9242-09173F13E4C5 n4:271B462A-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B4628-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Acceptor-Count
n4:271B4637-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B4638-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B4632-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B4633-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B4635-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B4634-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B4636-363D-11E5-9242-09173F13E4C5
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
488832-69-5
n3:category
n3:Bioavailability
n4:271B463D-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B463F-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B4640-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B463C-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B463B-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B463E-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B462C-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B4639-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B463A-363D-11E5-9242-09173F13E4C5